The Epoch Times BY KATABELLA ROBERTS
Johnson & Johnson suspended sales forecasts for its COVID-19 vaccine on April 19, citing a global supply surplus and uncertainty when it comes to future demand for the shot.
The company had previously predicted as much as $3.5 billion in 2022 sales from the single-dose vaccine, but demand for the shot has dwindled behind that of the Moderna and Pfizer vaccines.
In its quarterly earnings results on April 19, the company said the move will not impact shareholder earnings.
